IMEGLIMIN
IMEGLIMIN is a novel oral anti-diabetic medication belonging to the class of glimins. It operates by targeting mitochondrial bioenergetics, thereby enhancing glucose-stimulated insulin secretion and insulin sensitivity.IMEGLIMIN is indicated for the treatment of type 2 diabetes mellitus, either as monotherapy or in combination with other oral anti-diabetic agents or insulin, to improve glycemic control.
The recommended initial dosage of IMEGLIMIN is typically 1000 mg taken orally twice daily with meals. Dosage adjustments may be required based on individual patient response and tolerability.
IMEGLIMIN is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. It should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Patients with renal impairment may require dosage adjustments or close monitoring while using IMEGLIMIN. Additionally, caution should be exercised in elderly patients and those with hepatic impairment.
Common side effects of IMEGLIMIN may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Hypoglycemia may occur, particularly when used in combination with insulin or other anti-diabetic medications.
IMEGLIMIN may interact with other medications, including those metabolized by CYP2C8 and CYP3A4 enzymes. Co-administration with drugs that affect renal function or glucose metabolism may require dosage adjustments or close monitoring.
